Novel Entrectinib Trial Focuses on Gene Rearrangements Across Many Tumor Types

Tony Berberabe, MPH @OncBiz_Wiz
Published: Wednesday, Mar 30, 2016
Robert C. Doebele,
MD, PhD

Robert C. Doebele, MD, PhD

A decade ago, researchers believed molecular alterations occurred in only one or two cancer types. That way of thinking has changed, however, with the understanding that the same alterations, especially gene fusions, can occur across many different tumor types.

As a result, researchers have designed a recently launched clinical study into entrectinib, a first-inclass inhibitor of tropomyosin receptor kinases (Trk), as a basket trial in which the drug can be evaluated simultaneously for activity against three gene alterations and multiple tumor types.

STARTRK-2 (NCT02568267) is an open-label, phase II study in which patients with locally advanced or metastatic solid tumors are assigned to different baskets according to whether their tumors harbor rearrangements in one of three key genes—NTRK1/2/3, ROS1, or ALK.

To be eligible for the trial, participants who have those aberrations cannot have received prior therapy that inhibits their respective gene rearrangements; the exception is that prior treatment with crizotinib is permitted for patients with non– small cell lung cancer (NSCLC) with ALK or ROS1 rearrangements who only have progression in the central nervous system.

Investigators are seeking to enroll approximately 400 participants in three tumor categories: NSCLC, metastatic colorectal cancer (mCRC), and other types of tumors and sarcomas. The main patient populations will be participants with NSCLC and mCRC.

Entrectinib is a small-molecule inhibitor of three Trk kinases (TrkA/B/C), which are encoded by NTRK genes, as well as an inhibitor of ROS1 and ALK activity. Rearrangements in these genes are variously present in nearly a dozen tumor types including NSCLC, CRC, sarcomas, gastrointestinal stromal tumors, Spitz melanoma, and papillary thyroid carcinoma.1

“What we are seeing is that regardless of the originating tumor type, these oncogene-driven tumors behave similarly in their response to targeted drugs,” said Robert C. Doebele, MD, PhD, an investigator for the STARTRK-2 trial at the University of Colorado School of Medicine, where he is an associate professor in the Division of Medical Oncology. For rare or infrequent oncogenes, trial sponsors are not restricting enrollment to particular tumor types, added Doebele. “This seems to be a new paradigm in study design,” he said.

“Basket trials have gotten hot over the last couple of years,” noted Andrew Nelson, MD, PhD, an assistant professor in the Division of Laboratory and Pathology at the University of Minnesota.

The basket design takes full advantage of entrectinib’s demonstrated preliminary clinical activity across a range of different tumor types and molecular targets, leading to a high probability of success, said Doebele. In STARTRK- 2, the primary outcome measure is objective response rate; secondary endpoints include duration of response, progression-free survival, and overall survival.

Additionally, the trial design addresses the challenge of identifying cost-effective and clinically accurate methods of screening relatively large numbers of patients for gene alterations that may be relevant for a fraction of patients, Nelson indicated.

 

STARTRK-2 Trial Entrectinib Study in Multiple Solid Tumors

CNS indicates central nervous system; DOR, duration of response; ECOG, Eastern Cooperative Oncology Group; NGS, next-generation sequencing; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

Ignyta, the San Diego company developing entrectinib, has designed a protocol that consists of an immunohistochemistry (IHC) screening test to identify patients potentially eligible for therapy and a companion molecular diagnostic test to confirm the IHC results. The molecular test is available on a platform that is accessible to all laboratories with next-generation sequencing capability.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x